Immunai, biotecnológica de IA fundada en Israel, lanza colaboración con Boehringer Ingelheim para el descubrimiento de fármacos
La colaboración utilizará la plataforma de IA de célula única de Immunai para identificar dianas de células T en el cáncer y las enfermedades autoinmunes
Valoración
An Israeli-founded AI biotech firm is partnering with a major pharmaceutical player to apply its single-cell technology to drug discovery. The focus on T-cell targets for both cancer and autoimmune conditions suggests a dual therapeutic ambition. This deal signals deepening industry interest in AI-driven immunology platforms, and the actual targets identified will be the key metric to watch.